ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD09.8

D09.8

Billable

Carcinoma in situ of other specified sites

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D09.8 is a billable code used to indicate a diagnosis of carcinoma in situ of other specified sites.

Key Diagnostic Point:

Carcinoma in situ (CIS) refers to a group of abnormal cells that remain localized and have not invaded surrounding tissues. The term 'other specified sites' indicates that the carcinoma in situ is located in areas not specifically categorized under other ICD-10 codes. This condition is often identified through screening procedures and can occur in various organs, including the skin, breast, cervix, and gastrointestinal tract. The clinical significance of carcinoma in situ lies in its potential to progress to invasive cancer if left untreated. Surveillance protocols typically involve regular monitoring through imaging studies, biopsies, and clinical examinations to detect any signs of progression. The risk of progression varies depending on the site of the carcinoma, the histological type, and the patient's overall health. Early detection and intervention are crucial in managing carcinoma in situ effectively, as timely treatment can prevent the development of invasive cancer.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Variety of sites where carcinoma in situ can occur, leading to potential confusion in coding.
  • Need for precise documentation to differentiate between in situ and invasive carcinoma.
  • Variability in treatment protocols based on the site of carcinoma.
  • Potential for overlapping symptoms with other conditions, complicating diagnosis.

Audit Risk Factors

  • Inadequate documentation of the site of carcinoma.
  • Failure to document follow-up care and surveillance.
  • Misclassification of in situ versus invasive carcinoma.
  • Lack of clarity in pathology reports.

Specialty Focus

Medical Specialties

Oncology

Documentation Requirements

Detailed pathology reports, treatment plans, and follow-up notes.

Common Clinical Scenarios

Diagnosis of carcinoma in situ during routine screenings, management of treatment plans, and monitoring for progression.

Billing Considerations

Ensure accurate staging and grading of carcinoma in situ to guide treatment decisions.

Dermatology

Documentation Requirements

Photographic evidence of lesions, biopsy results, and treatment notes.

Common Clinical Scenarios

Identification of skin lesions during examinations, biopsy of suspicious areas, and management of skin carcinoma in situ.

Billing Considerations

Document the size, location, and characteristics of skin lesions for accurate coding.

Coding Guidelines

Inclusion Criteria

Use D09.8 When
  • According to ICD
  • 10 coding guidelines, carcinoma in situ codes should be used when there is definitive diagnosis through biopsy or imaging

Exclusion Criteria

Do NOT use D09.8 When
  • Exclusion criteria include any invasive carcinoma or conditions that do not meet the criteria for carcinoma in situ

Related ICD-10 Codes

Related CPT Codes

19120CPT Code

Excision, breast, tumor

Clinical Scenario

Used when excising a carcinoma in situ of the breast.

Documentation Requirements

Pathology report confirming carcinoma in situ and operative notes.

Specialty Considerations

Oncologists must ensure accurate staging and documentation of margins.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and enhancing the ability to track treatment outcomes and progression risks.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and enhancing the ability to track treatment outcomes and progression risks.

Reimbursement & Billing Impact

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and enhancing the ability to track treatment outcomes and progression risks.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the difference between carcinoma in situ and invasive carcinoma?

Carcinoma in situ refers to abnormal cells that have not invaded surrounding tissues, while invasive carcinoma has spread beyond the original site into nearby tissues.